课题基金 / 基金详情

CANCER CENTER SUPPORT

CANCER CENTER SUPPORT
癌症中心支持
批准号:
6328868
负责人:
DANIEL W NIXON
金额:
$231.19万
依托单位国家:
美国
项目类别:
财政年份:
1979
资助国家:
美国
项目状态:
已结题
起止时间:
1979-08-01 至 2001-11-30

项目摘要

项目成果

DANIEL W NIXON的其他基金

相似基金

相关文献

中文摘要
翻译
美国健康基金会癌症中心(AHFCC)是一个独特的基础 完全致力于癌症预防和治疗的研究中心 控制力。AHFCC的主要目标是降低发病率、发病率 和癌症死亡率,依赖于一种高度跨学科的方法 流行病学研究的结果针对哪些研究领域,在 使用生物学和分子方法的深度,以及适当的癌症 实施控制活动。因为大多数美国人的健康 基金会的支持来自同行评议的国家癌症 研究所(NCI)赠款和合同、上级组织和 AHFCC实际上是相同的。AHFCC的研究重点是 预防已知与生活方式有关的主要人类癌症: 即肺、口腔、食道、宫颈和胰腺;以及 受营养影响:即乳房、乳房、胃和结肠。这个 目前,AHFCC是唯一一个主要致力于 了解癌症预防的生物学和行为学 癌症控制所需的各个方面。因此,AHFCC提供了一个独特的 环境,23年来一直在进行研究,这是最近 NCI癌症预防审查小组公布的建议为 对制定减少温室气体排放国家战略至关重要 这个国家的癌症发病率。对AHFCC进行了研究 我们的四个高度互动的节目:1)烟草与环境 致癌,2)致癌机制,3)化学预防和 营养致癌,以及4)癌症控制和健康促进。 AHFCC的新目标是通过以下方式增加其在癌症控制方面的专业知识 增加一名行为心理学家,并加强其对 在新的癌症易感性计划中开发新的生物标记物 分子流行病学家的招募。这些研究项目 目前由9个AHF癌症中心支持赠款共享 资源:1)分析化学设施,2)生物安全和生物危害 设施,3)生物统计和计算设施,7)有机合成 设施,8)研究动物设施,9)科学信息和 编辑部。AHFCC活动分三场进行 地点:瓦尔哈拉达纳路1号内勒·达纳学院。纽约;东43街320号 和纽约第三大道675号,这两个城市分别容纳了 现有员工180人。在其癌症中心的续签申请中 支持赠款,AHFCC请求继续支持五年 为了扩大其独特的癌症跨学科研究方法 预防和探索一些重要的研究线索,这些线索是 以期进一步了解其生物学机制,以及 癌症控制新方法的发展。
英文摘要
The American Health Foundation Cancer Center (AHFCC) is a unique basic research center that is dedicated entirely to cancer prevention and control. The primary goal of the AHFCC, to reduce the incidence, morbidity and mortality of cancer, relies un a highly interdisciplinary approach in which research areas are targeted by epidemiologic findings, studied in depth using biological and molecular approaches, and appropriate cancer control activities are implemented. Since most of the American Health Foundation's support is derived from peer-reviewed National Cancer Institute (NCI) grants and contracts, the parent organization and the AHFCC are virtually identical. The AHFCC's research is focused upon prevention of the major human cancers known to be related to life-styles: i.e., lung, oral cavity, esophagus, cervix, and pancreas; and those affected by nutrition: i.e., breast, postulate, stomach, and colon. The AHFCC is, at present, the only cancer center principally dedicated to understanding both the biology of cancer prevention and the behavioral aspects required for cancer control. Thus, the AHFCC provides a unique environment that, for 23 years, has pursued research that underlies recent recommendations promulgated by the NCI Cancer Prevention Review Group as being critical for the development of a national strategy to reduce the incidence of cancer in this country. The research of the AHFCC is carried our in four highly interactive programs: 1) Tobacco and Environmental Carcinogenesis, 2) Mechanisms of Carcinogenesis, 3) Chemoprevention and Nutritional Carcinogenesis, and 4) Cancer Control and Health Promotion. New goals of the AHFCC are to augment its expertise in Cancer Control by the addition of a behavioral psychologist and strengthen its commitment to developing new biomarkers in the new program of Cancer Susceptibility by the recruitment of a molecular epidemiologist. These Research Programs are presently supported by nine AHF Cancer Center Support Grant Shared Resources: 1) Analytical Chemistry Facility, 2) Biosafety and Biohazard Facility, 3) Biostatistics and Computing Facility, 7) Organic Synthesis Facility, 8) Research Animal Facility, and 9) Scientific Information and Editorial Facility. AHFCC activities are conducted at three performance sites: the Naylor Dana Institute, 1 Dana Road, Valhalla. NY; 320 E. 43rd St., New York, NY; and 675 Third Ave., New York, NY, which accommodate a current staff of 180. In this renewal application of its Cancer Center Support Grant, the AHFCC requests continuing support for five years in order to expand its unique interdisciplinary research approach to cancer prevention and explore a number of important research leads which are anticipated to further understanding of the biological mechanisms of , and the development of new approaches to cancer control.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
START- STRATEGIC TIMING OF ANTIRETROVIRAL THERAPY
  • 批准号:
    8166579
  • 项目类别:
  • 资助金额:
    $0.07万
  • 财政年份:
    2009
  • 负责人:
    DANIEL W NIXON
  • 依托单位:
STUDY A5235: A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN THE
  • 批准号:
    8166560
  • 项目类别:
  • 资助金额:
    $1.02万
  • 财政年份:
    2009
  • 负责人:
    DANIEL W NIXON
  • 依托单位:
CLINICAL TRIAL: A PHASE III COMPARATIVE STUDY OF THREE NON-NUCLEOSIDE REVERSE TR
  • 批准号:
    8166580
  • 项目类别:
  • 资助金额:
    $0.95万
  • 财政年份:
    2009
  • 负责人:
    DANIEL W NIXON
  • 依托单位:
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/
  • 批准号:
    7950848
  • 项目类别:
  • 资助金额:
    $4.15万
  • 财政年份:
    2008
  • 负责人:
    DANIEL W NIXON
  • 依托单位:
海外基金